Phenotypic similarity-based approach for variant prioritization for unsolved rare disease: a preliminary methodological report

Author:

Lebreton Emeline1,Matalonga Leslie2,Hongnat Oscar1,Chahdil Maroua1,Piscia Davide3,Paramonov Ida,Ellwanger Kornelia4ORCID,Kohler Sebastian5,Robinson Peter6ORCID,Graessner Holm7ORCID,Beltran Sergi3ORCID,Lucano Caterina1,Hanauer Marc1,Rath Ana1ORCID,Lagorce David1ORCID

Affiliation:

1. INSERM

2. Centre Nacional d'anàlisi Genòmica

3. Centro Nacional de Análisis Genómico - Centro de Regulación Genómica (CNAG-CRG)

4. University Hospital Tübingen

5. Charité-Universitätsmedizin Berlin

6. The Jackson Laboratory

7. University of Tübingen

Abstract

Abstract Rare diseases (RD) have a prevalence of not more than 1/2000 in the European population, and are characterised by the difficulty of obtaining a correct and timely diagnosis. According to Orphanet, 72,5% of RD have a genetic origin although 35% of them do not yet have an identified causative gene. A significant proportion of patients suspected to have a genetic RD receive an inconclusive exome/genome sequencing. Working towards the International Rare Diseases Research Consortium (IRDiRC)’s goal for 2027 to ensure that all people living with a RD receive a diagnosis within one year of coming to medical attention, the Solve-RD project aims to identify the molecular causes underlying undiagnosed RD. As part of this strategy, we developed a phenotypic similarity-based variant prioritization methodology comparing submitted cases amongst them and with known RD in Orphanet. A 3-step programmatic cascade of phenotypic similarity calculations using The Human Phenotype Ontology (HPO), the Orphanet Rare Diseases Ontology (ORDO) and the HPO-ORDO Ontological Module (HOOM) was developed; genomics data reanalysis was performed by the RD-Connect Genome-Phenome Analysis Platform (GPAP). The methodology was tested in 4 exemplar cases, discussed with experts from European Reference Networks. Variants of interest (pathogenic or likely pathogenic) were detected in 8.8% of the 725 cases clustered by similarity algorithms, formulating diagnostic hypotheses that were validated in 42.1% of them and need further explorations in another 10.9%. Based on the promising results, we are devising an automated standardized phenotypic-based re-analysis pipeline to be applied to the entire unsolved cases cohort in Solve-RD.

Publisher

Research Square Platform LLC

Reference35 articles.

1. European Union. Regulation (EC) N°141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. 2000 [Internet]. [cited 30 Nov 2022]. Disponible sur: https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2000:018:0001:0005:en:PDF

2. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database;Nguengang Wakap S;Eur. J. Hum. Genet.,2020

3. Recommendations from the IRDiRC Working Group on methodologies to assess the impact of diagnoses and therapies on rare disease patients;Zanello G;Orphanet J. Rare Dis.,2022

4. Recommendations From The Rare 2030 - Foresight Study The Future Of Rare Diseases Starts Today - February 2021 - Rare2030.Eu/Recommendations

5. Work Package 5 Specifications for an integrated coding application with Orphacodes. www.rd-action.eu.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3